Featured Publications

INOVIO is focused on rapidly bringing to market precisely designed DNA medicines to potentially treat and protect people from diseases associated with HPV, cancer, and infectious diseases. In the last several years INOVIO has had its data published in several prominent peer-reviewed medical journals including:

Filter by Category


Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses
Science Translational Medicine — October 2012
Disease TargetCervical Dysplasia ProductVGX-3100
Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100
Molecular Therapy Oncolytics — January 2016
Disease TargetCervical Dysplasia ProductVGX-3100
Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy
Clinical Cancer Research — January 2018
Disease TargetCervical Dysplasia ProductVGX-3100
Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis
BMJ — July 2016
Disease TargetCervical Dysplasia ProductVGX-3100
Immune Therapy Targeting E6/E7 Oncogenes of Human Papillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis
Vaccines — January 2020
Disease TargetRRP ProductINO-3107
Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer
Clinical Cancer Research — January 2019
Disease TargetHead & Neck Cancer ProductMEDI0457
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial
The Lancet — September 2015
Disease TargetCervical Dysplasia ProductVGX-3100

Immuno-Oncology (Non HPV-Associated)

Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT
Molecular Therapy — November 2017
Disease TargethTERT ProductINO-5401
Highly Optimized DNA Vaccine Targeting Human Telomerase Reverse Transcriptase Stimulates Potent Antitumor Immunity
Cancer Immunology Research — September 2013
Disease TargethTERT ProductINO-5401
A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity
Molecular Therapy — February 2017
Disease TargetWT1 ProductINO-5401
CD8+ T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens
Molecular Therapy — March 2020
Disease TargetPSA ProductINO-5151
Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses
Human Vaccines — January 2011
Disease TargetPSA, PSMA ProductINO-5401

Infectious Diseases (Non HPV-Associated)

Synthetic Consensus HIV-1 DNA Induces Potent Cellular Immune Responses and Synthesis of Granzyme B, Perforin in HIV Infected Individuals
Molecular Therapy — March 2015
Disease TargetHIV ProductPENNVAX-GP
HIV-1 Env DNA Vaccine plus Protein Boost Delivered by EP Expands B- and T-Cell Responses and Neutralizing Phenotype In Vivo
PLoS ONE — December 2013
Disease TargetHIV ProductPENNVAX-GP
Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine
Vaccine — September 2011
Disease TargetHIV ProductPENNVAX-GP
Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers
The Journal of Infectious Diseases — March 2019
Disease TargetEbola ProductINO-4201
Protective Efficacy and Long-Term Immunogenicity in Cynomolgus Macaques by Ebola Virus Glycoprotein Synthetic DNA Vaccines
The Journal of Infectious Diseases — October 2018
Disease TargetEbola ProductINO-4201
Rapid response to an emerging infectious disease – Lessons learned from development of a synthetic DNA vaccine targeting Zika virus
Microbes and Infection — December 2018
Disease TargetZika ProductINO-4600
Zika-Induced Male Infertility in Mice Is Potentially Reversible and Preventable by Deoxyribonucleic Acid Immunization
The Journal of Infectious Diseases — July 2018
Disease TargetZika ProductINO-4600
DNA vaccination protects mice against Zika virus-induced damage to the testes
Nature Communications — June 2017
Disease TargetZika ProductINO-4600
In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine
npj Vaccines — November 2016
Disease TargetZika ProductINO-4600
A synthetic consensus anti–spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates
Science Translational Medicine — August 2015
Disease TargetMERS ProductINO-4700
Broad cross-protective anti-hemagglutination responses elicited by influenza microconsensus DNA vaccine
Vaccine — May 2018
Disease TargetInfluenza
An engineered bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a pneumonia challenge model
Nature Communications — September 2017
Disease TargetPseudomonas
Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus
The Journal of Infectious Diseases — March 2016
Disease TargetChikungunya
Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy
Scientific Reports — July 2015
Disease TargetDengue
IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T-cell frequency and increases virus-specific T-cell responses
Journal of Hepatology — February 2020
Disease TargetHepatitis C ProductGLS-6150
Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial
The Lancet Infectious Diseases — July 2019
Disease TargetMERS ProductINO-4700
Safety and Immunogenicity of an Anti–Zika Virus DNA Vaccine — Preliminary Report
The New England Journal of Medicine — October 2017
Disease TargetZika ProductINO-4600

dMAb™ (DNA-Encoded Monocolonal Antibodies)

Other Development Candidates

DNA-encoded bispecific T cell engagers and antibodies present long-term antitumor activity
JCI Insight — April 2019
Disease TargetHER2

Delivery Technology/Proprietary Smart Device

Electroporation delivery of DNA vaccines: prospects for success
Current Opinion in Immunology — June 2011
Disease TargetDelivery ProductCELLECTRA®
A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle
Vaccine — September 2011
Disease TargetDelivery ProductCELLECTRA
Integration of needle-free jet injection with advanced electroporation delivery enhances the magnitude, kinetics, and persistence of engineered DNA vaccine induced immune responses
Vaccine — June 2019
Disease TargetDelivery ProductCELLECTRA


Immunogenicity of a DNA vaccine candidate for COVID-19
Nature Communications — May 2020
Disease TargetCOVID-19 ProductINO-4800
571. Safety and Immunogenicity of INO-4800, a COVID-19 DNA Vaccine as a Primary Series and Booster
Open Forum Infectious Diseases — December 2021
Disease TargetCOVID-19 ProductINO-4800
SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial
The Journal of Infectious Diseases — January 2022
Disease TargetCOVID-19 ProductINO-4800
INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants
npj Vaccines — October 2021
Disease TargetCOVID-19 ProductINO-4800